EW - Tagesausblick Dax, Mittwoch 18. Juni
Seite 19 von 35 Neuester Beitrag: 25.04.21 11:13 | ||||
| Eröffnet am: | 18.06.03 08:10 | von: first-henri | Anzahl Beiträge: | 857 |
| Neuester Beitrag: | 25.04.21 11:13 | von: Angelikauqy. | Leser gesamt: | 44.130 |
| Forum: | Börse | Leser heute: | 10 | |
| Bewertet mit: |  | |||
| Seite: < 1 | ... | 16 | 17 | 18 | | 20 | 21 | 22 | ... 35 > | ||||
Auf dem Titelblatt ein Bulle und als Überschrift "DER BULLE ist zurück"
Wie lange bleibt er?
Wenn die Illus hypen geht es meist rapido bergab.
Gruß, hardyman
Optionen
| Boardmail an "hardyman" |
Wertpapier: Wave auf DAX (Perf.) [D |
konnte heute nachmittag nicht,obwohl heiss. predator und blue jack tot.
war ne topchance,aber blind....
gruss buttman
USA Erstanträge auf Arbeitslosenhilfe zum 14.06. (14:30)
Frühindikatoren Mai (16:00)
Philadelphia Fed Index Juni (18:00)
Staatshaushalt Mai (20:00)
und nun,na ja. not overnight.
gruss buttman
18 JUN 22:10 GE unit acquires Monitoring Automation Systems
18 JUN 22:10 EchoStar tries to block News Corp-Hughes
18 JUN 22:09 Metals shares end five-session winning streak
18 JUN 22:09 Bear, Morgan lead financial sector to lower close
18 JUN 22:09 *AT&T TO SELL EUROTEL PRAHA STAKE CESKY TEL FOR $525 MLN
18 JUN 22:07 Biotech stocks close sharply lower
18 JUN 22:01 *S&P 500 UNOFFICIAL CLOSE DOWN 1.8 TO 1,009.9
18 JUN 22:01 *NASDAQ UNOFFICIAL CLOSE UP 8.7 TO 1,677.2
18 JUN 22:01 *DOW INDUSTRIALS UNOFFICIAL CLOSE DOWN 31 TO 9,291
NEW YORK (AFX) -- The Nasdaq scored gains for a third straight session on
Wednesday to end at fresh 13-month highs while the Dow Industrials was held back
by an ugly profit warning from Eastman Kodak.
Chip and networking stocks paced the tech rally following positive brokerage
remarks. Airline shares also rallied thanks to analyst upgrades in the group.
"Those positive comments are providing more confidence to buy on the dip. The
semis really started to move and that got the Nasdaq going," remarked Peter
Boockvar, equity strategist at Miller, Tabak & Co.
Sellers took down brokerage stocks amid heady losses in Morgan Stanley and Bear
Stearns following their profit reports. And gold issues logged losses as gold
for August delivery tumbled $6 to $357.8. and
The Dow Jones Industrial Average broke a two-day winning streak, surrendering
29 points, or 0.3 percent, to 9,293 after falling up to 91 points intraday.
The Nasdaq Composite rose 8 points, or 0.5 percent, to 1,677 after declining as
much as 15 points early in the session. The Nasdaq 100 Index closed up 8
points, or 0.7 percent, to 1,247.
Keith Keenan, vice president of institutional trading at Wall Street Access,
said structural forces have been pushing stocks higher.
"The tax cuts, the Fed forcing down long-term rates and performance anxiety
among money managers that are underperforming their benchmarks are dominating
the market," Keenan said. "These forces will only help stocks in the short
term."
He cautioned that a sustainable recovery will only be possible if end demand
picks up. He feels that investors are overestimating the economy's potential.
Terry Danish, technical analyst at Maxim Group, said the market's rise is no
longer in the early stages and that the stock-picking environment has thus
become more selective.
"A greater emphasis has recently been placed on value, perhaps showing that the
early speculative phase seen over the past month or two may be slowing," Danish
pointed out.
The Standard & Poor's 500 Index lost 0.2 percent while the Russell 2000 Index
of small-capitalization stocks fell 0.1 percent.
Volume totaled 1.46 billion on the NYSE and 2.05 billion on the Nasdaq Stock
Market. Decliners outpaced advancers by 20 to 13 on the NYSE while winners
roughly matched losers on the Nasdaq.
Kodak slides; Clorox, NY Times also decline
Kodak slid 10 percent after slashing its second-quarter earnings projections to
25 to 35 cents a share from its prior forecast of 60 to 80 cents a share. The
Dow component blamed significantly lower-than-anticipated consumer film and
photographic paper sales in Asia as reason for the glaring shortfall. The firm
conceded that economic weakness, reduced tourism and geopolitical turmoil would
continue to negatively impact sales and earnings for the rest of the year.
Meanwhile, Clorox Co. fell 6.3 percent after trimming its profit projections
for the fourth-quarter and full year, citing the negative impact of the wet
spring, which reduced consumer demand for auto and seasonal products.
Still reeling from its recent editorial shake-up, The New York Times warned
that second-quarter earnings would miss Wall Street's expectations as the Iraqi
war, SARS (severe acute respiratory syndrome) and a tough job market all
contributed in curtailing advertising growth. Shares gave up 6.9 percent.
Computer services firm EDS Corp. unveiled restructuring efforts, which will
result in a charge in 2003 and the elimination of about 2 percent of its
workforce. EDS backed its second-quarter profit outlook while its earnings
projections for the second half of the year were lighter compared with Wall
Street's consensus estimates. The stock climbed 8.4 percent.
The battle between Oracle and PeopleSoft raged on, grabbing headlines in the
software sector.
Oracle upped its bid for PeopleSoft to $6.3 billion in cash, up from the $5.1
billion originally offered on June 6. Oracle also said it would file suit
against PeopleSoft, its board, and J.D. Edwards in response to their suits
against it. J.D. Edwards has agreed to merge with PeopleSoft. All of the
mentioned stocks notched gains, led by PeopleSoft's 5.3-percent advance.
Brokers retreat after MWD, Bear results
Two major brokerages kicked off the second-quarter earnings season by unveiling
their results Wednesday morning.
Morgan Stanley posted a second-quarter profit of 55 cents a share, including a
pre-tax charge of 16 cents a share. Analysts surveyed by Thomson First Call had
projected earnings of 68 cents a share. The stock fell 5.7 percent in recent
trades.
And Bear Stearns reported a second-quarter profit that handily topped analysts'
expectations. Shares gave up 2.1 percent.
In other earnings news, Best Buy checked in with a first-quarter profit that
surpassed Wall Street's estimate. For the second-quarter, the electronics
retailer's profit projection matched Wall Street's. Shares eased 0.5 percent.
Read for the latest individual stock action.
Chips, airlines boosted by upgrades
Chip stocks led the tech sector higher amid upgrades in the communications
group from Lehman Bros.
Applied Micro Circuits , PMC-Sierra and Vitesse Semiconductor were all raised
to "equal weight" ratings from "underweight" on belief the companies' telecom
businesses will improve. Vitesse checked in with the biggest rally, climbing
12.5 percent.
In the equipment segment, leader Applied Materials climbed 2.4 percent and
rival KLA-Tencor put on 2.3 percent. Industry tracker Semiconductor Equipment
and Materials International (SEMI) announced late Tuesday that North
American-based manufacturers of chip equipment saw a second straight month of
declines in orders in May.
Cisco Systems took networkers higher, rallying 3.6 percent after Prudential
bumped up its price target and fiscal 2004 profit estimate on the stock.
Apple Computer was also a standout, tacking on almost 6 percent following an
upgrade from Needham & Co. to a "buy" from a "hold."
In the airline sector, AMR Corp. and America West were on a tear following
upgrades from Merrill Lynch to a "buy" rating from a "neutral." AMR tacked on
5.8 percent and America West rallied 16.6 percent.
Meanwhile, Lehman Bros. hoisted its price targets on a number of industrial
conglomerates, including Dow components General Electric , Honeywell and 3M ,
on expectations the general economy will improve in the second half of the year.
Among the mentioned names, Honeywell climbed 1.5 percent, GE edged down 0.3
percent and 3M put on 0.9 percent.
Mattel fell 4.1 percent following a downgrade from UBS to a "neutral" from a
"buy" while Host Marriott slid 4.4 percent after a UBS downgrade to a "reduce"
on valuation worries.
Treasurys make it three in a row
Government bonds slipped for a third straight session, with longer-maturity
issues again taking the biggest hit.
The 10-year Treasury note slid 25/32 to yield 3.355 percent while the 30-year
government bond plunged 1 18/32 to yield 4.39 percent.
No economic news is set for release Wednesday. The balance of the week will see
mostly second-tier reports, including May leading economic indicators and the
Philly Fed index for June.
Most market participants are projecting a quarter-point rate cut when the
Federal Reserve meets next week to decide on monetary policy. Check
The National Bureau of Economic Research said it needs more time to determine
whether the recession that began in March 2001 is now over.
"Additional time is needed before interpreting the movements of the economy over
the past two years," the NBER said.
In the currency sector, the U.S. dollar edged higher against its major
counterparts, climbing 0.3 percent to 117.78 yen while the euro declined 0.8
percent to $1.1685.
This story was supplied by CBSMarketWatch. For further information see
www.cbsmarketwatch.com.
Jabil Circuit reported third-quarter net income after the closing bell of
$4.5 million, or 2 cents per share. That compared with net income of $20.8
million, or 10 cents per share, in the same period the year before. Revenue at
the provider of electronic manufacturing services rose to $1.2 billion during
the period versus $850.6 million in the third quarter of fiscal 2002. Shares of
Jabil finished Wednesday's regular trading session up 29 cents at $24.21.
This story was supplied by CBSMarketWatch. For further information see
www.cbsmarketwatch.com.
WASHINGTON (AFX) -- Economists still haven't determined when the recession
that began in March 2001 ended. Or whether it has ended at all.
The group considered the most authoritative voice on business cycles said
Wednesday it needs "additional time ... before interpreting the movements of the
economy over the past two years."
"According to the most recent data, the U.S. economy continues to experience
growth in income and output but employment continues to decline," according to
the business cycle timing committee of the private National Bureau of Economic
Research.
Delays in declaring the beginning and ends of recessions are common. The NBER is
trying to write history, not make news.
"They are laying the groundwork for declaring an end to the '01 recession," said
Irwin Kellner, chief economist at CBS.MarketWatch.com and the Weller professor
of economics at Hofstra University. While some observers may say that the
recession obviously ended in the fourth quarter of 2001 -- when gross domestic
product began growing again after declining for the previous three quarters --
for these academics it's not that simple.
"A recession is a significant decline in activity spread across the economy,
lasting more than a few months, normally visible in real GDP, real income,
employment, industrial production, and wholesale-retail sales," the NBER
committee says.
While GDP, incomes and sales have been growing over the past year, employment is
still declining and production has grown only fitfully.
Kellner said the most recent memo reduces the relative importance of employment
as the main indicator by elevating incomes to equal status. In addition, the
committee, for the first time, refers to giving some weight to an unpublished
estimate of monthly GDP produced by Macroeconomic Advisers. The government
publishes only quarterly estimates of GDP.
The committee said determining the end of the recession would first depend on
concluding that the economy has surpassed the peak in March 2001. Incomes, sales
and GDP are now higher than they were in 2001 in real terms, while employment
and output have not recovered.
The committee typically updates its memo once a month. There was no update in
May, due to scheduling conflicts, the NBER said. However, there were whispers
that the committee could not agree on the wording of the May memo.
Also, one member of the committee, Gregory Mankiw, left Harvard and the business
cycle committee to head President Bush's Council of Economic Advisers. He's been
replaced by David and Christina Romer, both economists at University of
California at Berkeley.
This story was supplied by CBSMarketWatch. For further information see
www.cbsmarketwatch.com.
das mit der citi ist natürlich mist.wuerde mich wahnsinnig machen.
aber so wie ich es überflogen habe, hast du doch schon bis ca. 16.00 richtig fett
eingesammelt.die negativen waren dagegen doch eher zu verkraften.oder willst du,dass die emis an dir pleite gehen.
werde morgen mal langsam wieder was tun.
glückwunsch an alle,die ihr konto fetter gemacht haben.
gruss buttman
NEW YORK (dpa-AFX) - Gesenkte Unternehmensprognosen haben am Mittwoch die
Anleger verunsichert und die Kurse an der Wall Street gedrückt. Der Dow Jones
Industrial Average (DJIA) verlor bis Handelsende 0,3 Prozent auf
9.293,80 Punkte. Der S&P 500 sank um 0,2 Prozent auf 1.010,09 Zähler.
Die Analysten von Lehman Brothers haben für den S&P 500 ein
Zwölf-Monats-Kursziel von 1.100 genannt. Die Aktienexperten unterstellen den
derzeit im Index notierten Unternehmen für das laufende Jahr ein Gewinnwachstum
von fünf Prozent. Für 2004 gehen sie von knapp acht Prozent aus.
Die Aktie des Fotokonzerns Eastman Kodak brach um 10,1
Prozent auf 28,77 Dollar ein, nachdem das Unternehmen seine Gewinnprognose für
das zweite Quartal gesenkt hatte. Beim operativen Gewinn geht Kodak nun von 25
bis 35 Cent je Aktie aus, nachdem es bislang von 60 bis 80 Cent ausgegangen war.
Damit war das Papier das Schlusslicht im Dow.
Zu den Gewinnern zählten Tabakaktien. Ein Berufungsgericht im US-Bundesstaat
Missouri hat am Dienstag die Schadensersatzklage einer Raucherin gegen die
Zigarettenhersteller Philip Morris USA, R.J. Reynolds Tobacco Co.
und Brown and Williamson Tobacco Co. zurückgewiesen. Altria
als Mutter von Philip Morris zogen als Tagessieger um 2,7 Prozent auf
44,24 Dollar an, R.J. Reynolds gewannen 3,4 Prozent auf 36,79 Dollar.
Der IT-Dienstleister Electronic Data Systems Corp.(EDS)
hat angesichts fallender Umsatzzahlen jährliche Einsparungen von 230 Millionen
Dollar und rund die Streichung von rund 2.740 Stellen angekündigt. Die Aktie
reagierte darauf mit einem Plus von 7,6 Prozent auf 24,20 Dollar.
Banken waren unter Druck. Die amerikanische Investmentbank Bear Stearns
hatte im zweiten Quartal die Gewinnerwartungen übertroffen.
Die Aktie verlor dennoch drei Prozent auf 80,01 Dollar.
Morgan Stanley Dean Witter büßten 5,6 Prozent auf 46,89
Dollar ein. Der Bank ist der Gewinn im zweiten Geschäftsquartal bei etwas
höheren Erträgen eingebrochen. Das am 31. Mai abgelaufene Quartal wurde durch
eine Abschreibung in Höhe von 287 Millionen Dollar vor Steuern aus dem
Flugzeugfinanzierungsgeschäft belastet.
Mit einem Gewinn von 0,71 Dollar je Aktie habe MSDW immerhin die
Markterwartungen leicht übertroffen, lobten die Analysten von U.S. Bancorp Piper
Jaffray. Vor allem das Fixed-Income-Geschäft habe zu dem Ergebnis beigetragen
und die schwächer als erwartet ausgefallenen Beiträge des Investment Bankings,
des Kreditkartenbereichs und der Vermögensverwaltung teilweise
ausgeglichen./ak/hi
BOSTON (AFX) -- Biotechnology stocks fell sharply Wednesday, with shares of
MedImmune sliding nearly 7 percent after some analysts made negative comments
about the company's newly approved flu vaccine.
The Amex Biotechnology Index dropped 3.8 percent to 464.92, and the Nasdaq
Biotechnology Index lost 3.6 percent to 714.66.
Shares of MedImmune tumbled $2.59, or 6.7 percent, to $36.12. MedImmune on
Tuesday won approval for a nasal-spray flu vaccine, called FluMist.
Pharmaceutical company Wyeth will co-market FluMist with MedImmune.
Wyeth shares slipped 63 cents to $48.53.
Analyst Joel Sendek at Lazard Freres said he expects sales of FluMist to
disappoint, and he recommended selling MedImmune shares.
"We believe that generating sales this year will be particularly challenging,
given that MedImmune and Wyeth have not had time to launch a full marketing
campaign to generate consumer and provider demand," Sendek wrote in a note to
clients.
Analyst Dennis Harp at Deutsche Bank Securities said some investors may have
been concerned because the Food and Drug Administration's approval requires that
FluMist be given in two doses when it's used to vaccinate children ages 5 to 8.
FluMist was approved for healthy children and adults ages 5 to 49.
Two doses will make FluMist more expensive for the age group for which the
nasal-spray flu vaccine "has the greatest appeal," Harp said in a note to
clients.
Harp said the FluMist approval was positive for MedImmune, but he downgraded
shares to "hold" from "buy" because he doesn't expect any "major catalysts
within the next five months that could drive further appreciation of the stock."
Still, some analysts remain optimistic about FluMist.
"We believe that the newsflow and excitement that will surround FluMist's first
season on the market will make MedImmune a top performer in the second half of
2003," analyst Phil Nadeau at SG Cowen wrote in a note to clients.
Elsewhere, shares of Cell Therapeutics plummeted $1.96, or 15.7 percent, to
$10.50. The Seattle-based biotech firm late Tuesday said it planned to raise
$100 million through an issuance of debt that could be converted into Cell
Therapeutics stock. Cell Therapeutics also said Tuesday it would acquire
Novuspharma S.p.A., an Italian biotech firm.
In the pharmaceutical sector, stocks were unable to build on big gains posted on
Monday and Tuesday. The Amex Pharmaceutical Index ended unchanged at 347.10.
Shares of Pfizer eased 13 cents to $36.05. Pfizer shares had jumped Tuesday
after the No. 1 drugmaker used its meeting with analysts to highlight the
potential of its new medications.
This story was supplied by CBSMarketWatch. For further information see
www.cbsmarketwatch.com.